Cidara Therapeutics Inc. (NASDAQ: CDTX) is 30.50% higher on its value in year-to-date trading and has touched a low of $1.82 and a high of $4.45 in the current 52-week trading range. The question becomes, what are the chances the stock will continue to grow shareholders’ wealth in the market. Here’s what analysts think will happen to its price in the coming time. The CDTX stock was last observed hovering at around $2.70 in the last trading session, with the day’s loss setting it -0.09% off its average median price target of $6.00 for the next 12 months. It is also 73.9% off the consensus price target high of $10.00 offered by 5 analysts, but current levels are 47.8% higher than the price target low of $5.00 for the same period.
Currently trading at $2.61, the stock is 5.07% and 4.09% above its SMA20 and SMA50 respectively. However, with a daily trading volume of 6.95 million and changing -3.33% at the moment leaves the stock -9.60% off its SMA200. CDTX registered 9.21% gain for a year compared to 6-month loss of -9.06%. The firm has a 50-day simple moving average (SMA 50) of $2.4964 and a 200-day simple moving average (SMA200) of $2.5120.
The stock witnessed a 11.54% gain in the last 1 month and extending the period to 3 months gives it a 30.50%, and is 13.97% up over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 12.61% over the week and 8.47% over the month.
Cidara Therapeutics Inc. (CDTX) has around 79 employees, a market worth around $123.53M and $12.10M in sales. Distance from 52-week low is 43.41% and -41.35% from its 52-week high. The company has generated returns on investments over the last 12 months (-405.90%).
Cidara Therapeutics Inc. (CDTX) Analyst Forecasts
Analyst recommendations provided by FactSet shows that the consensus forecast for Cidara Therapeutics Inc. (CDTX) is a “Buy”. 5 analysts offering their recommendations for the stock have an average rating of 1.70, where 0 rate it as a Hold and 0 think it is a “Overweight”. 5 of the analysts rate the stock as a “Buy”. 0 analysts have rated the stock as a Sell or Underperform.
Cidara Therapeutics Inc. is expected to release its quarterly report on 08/11/2021 and quarterly earnings per share for the current quarter are estimated at -$0.26 with sales reaching $10.5M over the same period.The EPS is expected to shrink by -27.60% this year, but quarterly earnings will post 77.10% year-over-year. Quarterly sales are estimated to grow 315.00% in year-over-year returns.
Cidara Therapeutics Inc. (CDTX) Top Institutional Holders
88 institutions hold shares in Cidara Therapeutics Inc. (CDTX), with 8.99M shares held by insiders accounting for 18.72% while institutional investors hold 67.36% of the company’s shares. The shares outstanding are 44.17M, and float is at 35.34M with Short Float at 4.32%. Institutions hold 54.75% of the Float.
The top institutional shareholder in the company is BVF Inc. with over 3.74 million shares valued at $7.48 million. The investor’s holdings represent 7.78% of the CDTX Shares outstanding. As of Dec 30, 2020, the second largest holder is Bellevue Group AG with 2.82 million shares valued at $5.64 million to account for 5.87% of the shares outstanding. The other top investors are 5AM Venture Management, LLC which holds 2.01 million shares representing 4.18% and valued at over $4.01 million, while Omega Fund Management (US) Inc. holds 4.17% of the shares totaling 2.01 million with a market value of $4.01 million.
Cidara Therapeutics Inc. (CDTX) Insider Activity
A total of 2 insider transactions have happened at Cidara Therapeutics Inc. (CDTX) in the last six months, with sales accounting for 0 and purchases happening 2 times. The most recent transaction is an insider sale by Abdollahian Neil ,the company’sChief Business Officer. SEC filings show that Abdollahian Neil sold 1,469 shares of the company’s common stock on Apr 01 at a price of $2.66 per share for a total of $3908.0. Following the sale, the insider now owns 57471.0 shares.
Cidara Therapeutics Inc. disclosed in a document filed with the SEC on Apr 01 that Oien Jessica (General Counsel & Secretary) sold a total of 1,177 shares of the company’s common stock. The trade occurred on Apr 01 and was made at $2.66 per share for $3131.0. Following the transaction, the insider now directly holds 7764.0 shares of the CDTX stock.
Still, SEC filings show that on Apr 01, Daruwala Paul (Chief Operating Officer) disposed off 593 shares at an average price of $2.66 for $1577.0. The insider now directly holds 50,531 shares of Cidara Therapeutics Inc. (CDTX).
Cidara Therapeutics Inc. (CDTX): Who are the competitors?
The company’s main competitors (and peers) include Spectrum Pharmaceuticals Inc. (SPPI) that is trading 45.05% up over the past 12 months. Short interest in the company’s stock has fallen -3.92% from the last report on Feb 11, 2021 to stand at a total of 1.59 million short shares sold with a short interest ratio of 1.04.